Jiangsu CoWin Biotech Co., Ltd. (SHA:688426)

Jiangsu CoWin Biotech Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	-	161.28	255.47	348.34	1,032	127.83
Short-Term Investments	-	306.8	60.54	90.01	-	-
Trading Asset Securities	-	420.14	417.04	545.28	402.59	233.42
Cash & Short-Term Investments	756.03	888.22	733.05	983.64	1,434	361.25
Cash Growth	23.73%	21.17%	-25.48%	-31.41%	297.00%	5.63%
Accounts Receivable	-	59.54	43.28	58.96	129.64	36.56
Other Receivables	-	2.2	2.45	-	0.31	-
Receivables	-	61.73	45.72	58.96	129.95	36.56
Inventory	-	48.77	45.87	32.04	52.53	32.62
Other Current Assets	-	34.71	8.76	10.04	10.05	7.72
Total Current Assets	-	1,033	833.4	1,085	1,627	438.16
Property, Plant & Equipment	-	342.02	381.13	394.39	246.43	159.44
Long-Term Investments	-	29.35	296.81	256.71	-	-
Goodwill	-	1.08	1.08	-	4.27	-
Other Intangible Assets	-	48.81	49.97	29.77	29.35	30.15
Long-Term Deferred Tax Assets	-	27.18	32.5	29.83	17.11	4
Long-Term Deferred Charges	-	12.6	20.73	24.8	11.36	13.82
Other Long-Term Assets	-	2.3	2.52	2.04	20.06	3.2
Total Assets	-	1,497	1,618	1,822	1,955	648.77

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	-	9.95	13.48	47.53	44.07	10.55
Accrued Expenses	-	23.03	23.1	16.69	21.69	22.12
Short-Term Debt	-	4	6.01	-	-	-
Current Portion of Leases	-	5.91	12.12	13.65	9.05	5.67
Current Income Taxes Payable	-	-	-	-	9.56	8.21
Current Unearned Revenue	-	25.01	9.63	4.48	5.75	10.28
Other Current Liabilities	-	6.16	19.65	2.51	3.03	3.58
Total Current Liabilities	-	74.07	84	84.86	93.15	60.41
Long-Term Leases	-	4.54	9.71	19.31	31.72	34.33
Long-Term Unearned Revenue	-	52.53	30.25	30.11	29.58	5.67
Long-Term Deferred Tax Liabilities	-	7.21	7.75	8.32	9.1	0.06
Other Long-Term Liabilities	-	0.12	0.09	0.06	0.05	0.04
Total Liabilities	-	138.47	131.79	142.67	163.6	100.51

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	-	112.49	112.49	112.23	93.52	69.87
Additional Paid-In Capital	-	1,391	1,394	1,391	1,393	344.45
Retained Earnings	-	-104.54	2.87	160.08	293.13	133.87
Treasury Stock	-	-47.67	-43.66	-	-	-
Comprehensive Income & Other	-	0.3	0.33	0.3	0.27	0.07
Total Common Equity	1,318	1,351	1,466	1,664	1,780	548.26
Minority Interest	-	7.18	20.56	15.88	11.31	-
Shareholders' Equity	1,325	1,358	1,486	1,680	1,792	548.26
Total Liabilities & Equity	-	1,497	1,618	1,822	1,955	648.77

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	43.35	14.45	27.84	32.95	40.77	39.99
Net Cash (Debt)	712.69	873.77	705.21	950.68	1,393	321.25
Net Cash Growth	21.05%	23.90%	-25.82%	-31.77%	333.73%	-6.07%
Net Cash Per Share	6.50	7.97	6.32	8.45	15.00	3.81
Filing Date Shares Outstanding	111.58	109.93	110.11	112.49	112.23	83.85
Total Common Shares Outstanding	111.58	109.93	110.11	112.23	112.23	83.85
Working Capital	-	959.36	749.41	999.82	1,534	377.75
Book Value Per Share	11.99	12.29	13.31	14.82	15.86	6.54
Tangible Book Value	1,270	1,301	1,415	1,634	1,747	518.11
Tangible Book Value Per Share	11.55	11.84	12.85	14.56	15.56	6.18
Buildings	-	216.23	235.28	234.89	0.66	0.66
Machinery	-	216.99	207.97	188.41	133.11	75.91
Construction In Progress	-	0.63	0.37	-	110.9	64.81

Data Source: S&P Global Market Intelligence Last updated: Oct 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 5, 2026

Data Sources Report a data error